Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fuzuloparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fuzuloparib (IRuiyi) is a potent anti-neoplastic agent. It is formulated as capsules for oral route of administration. IRuiyi is indicated for the platinum-sensitive recurrent ovarian cancer, fallopian tube cancer and primary patients with germline BRCA mutation who have undergone second-line and above chemotherapy treatments.
Fuzuloparib (SHR-3162) is under development for the treatment of advanced esophageal squamous cell carcinoma , squamous non-small cell lung cancer, advanced solid malignancies including advanced pancreatic adenocarcinoma, HER2-negative metastatic breast cancer, recurrent or metastatic gastric cancer, prostate cancer, metastatic castration-resistant prostate cancer, recurrent ovarian cancer, peritoneal cancer, small cell lung cancer, fallopian tube cancer, glioblastoma multiforme (GBM) and refractory metastatic triple negative breast cancer. The therapeutic candidate is administered orally. The drug candidate is a small molecule which acts by targeting PARP-1 and PARP-2.
It was under development for the treatment of metastatic pancreatic cancer.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Fuzuloparib’s drug-specific PTSR and LoA scores, buy the report here.